At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
rAAV2tYF-CB-hRS1biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis
In Brief
A Phase 2 clinical trial evaluating rAAV2tYF-CB-hRS1 for X-linked Retinoschisis. Completed, enrolled 27 participants across 9 sites.
Detailed Summary
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose escalation format.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsX-linked Retinoschisis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartMay 2015
Primary CompletionApr 2019
Study CompletionMay 2023
TodayJul 2026
First PostedApr 15, 2015
Enrollment StartMay 1, 2015
Primary CompletionApr 1, 2019
Study CompletionMay 9, 2023
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 11.2 years ago
Interventions
rAAV2tYF-CB-hRS1biological
adeno-associated virus vector expressing retinoschisin